Skip to main content

Technical View: Nifty forms bearish candle for second straight day, experts say index can break 14,000

 

Volatility has spiked above 24, pausing the positive momentum. and needs to be below 20 for the index to climb again, Chandan Taparia of Motilal Oswal has said.

The Nifty50 fell sharply for the second day running due to selling pressure and lost more than 150 points on January 18. The correction was seen across sectors, with the Nifty metal falling the most with a 4 percent loss. Bank, financial services, auto, IT, realty and pharma indices were down 1-3 percent.

After opening higher at 14,453.30, the Nifty hit the day's high of 14,459.15 in early trade only to slip into the red. The index tried to recoup losses in the afternoon but fell sharply in the last hour and closed 152.40 points, or 1.06 percent, lower at 14,281.30.



The index formed a bearish candle on the daily charts as the closing was lower than opening levels. Experts advised caution as the Union Budget 2021 nears and said the volatility is likely to continue in the coming days.

"Bears appear to be slowly tightening their grip on the markets as intraday recovery towards 14,400 levels met with huge selling pressure in post luncheon session, which paved the way for new intraday low of 14,222 levels. Hence, the trajectory of this market might have shifted from buy-on-dips to sell-on-rallies," Mazhar Mohammad, Chief Strategist–Technical Research & Trading Advisory at Chartviewindia.in told Moneycontrol

Therefore, stability should not be expected unless the index closes above 14,459 levels, he said.

As the index is down more than 300 points in the last two sessions, some sideways consolidation should be expected the next day unless it breaches 14,222 levels, Mohammad said.

If 14,222 is violated, then the slide shall get extended towards 14,100 levels. However, a bounce towards 14,400 can be an opportunity to initiate fresh shorts for bigger targets placed in the 13,950–13,800 zone.

Volatility has gradually been inching higher ahead of the Union Budget, with India VIX up by 1.60 percent from 24.01 to 24.39 levels. "Volatility has spiked above 24, which is causing some pause in the positive momentum and needs to cool down below 20 zone," said Chandan Taparia of Motilal Oswal.

On the options front, maximum Put open interest was at 14,000 followed by 13,000 strike, while maximum Call open interest was at 15,000 followed by 14,500 strike. Call writing was seen at 14,500 then 14,400 strike, while Put writing was seen at 14,100 and unwinding at 13,800 strike.

The above options data indicated that the Nifty could see an immediate trading range of 14,100-14,500.

The Bank Nifty opened moderately higher at 32,275.15 but could not surpass its hurdle of 32,500 even after a positive move of HDFC Bank and drifted towards 31,650. It moved hand-in-hand with the broader market, with all the banking stocks trading in the red barring HDFC Bank.

It closed the day down 435 points, or 1.35 percent, at 31,811.80 and formed a bearish candle on the daily scale.

"The Bank Nifty continues to form lower tops-lower bottoms from the last two sessions. Now till it remains below 32,000, weakness could be seen towards 31,500 and 31,250, while on the upside, hurdle is seen at 32,200 and 32,500 levels," Chandan Taparia, Vice President | Analyst-Derivatives at Motilal Oswal Financial Services said.

A positive setup was seen in UPL, PVR, Reliance Industries, Eicher Motors, Titan, Jubilant Foodworks and HDFC Bank. Weakness was seen in Indiabulls Housing Finance, M&M Financial, Petronet LNG, Tata Steel, ONGC, NMDC, LIC Housing Finance, Mahanagar Gas, Manappuram Finance, JSW Steel, Hindalco, Escorts, IndusInd Bank, Bajaj Finance, Glenmark Pharma, Dr Reddy's Labs and Cadila Healthcare, he added.

Comments

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...